Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VTX2735 · 2 trials · 2 indications
Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation
| Arm | Type | Description |
|---|---|---|
| Cohort A | EXPERIMENTAL | - |
| Cohort B Treatment Group B1 | EXPERIMENTAL | - |
| Cohort B Treatment Group B2 | EXPERIMENTAL | - |
| Cohort C Treatment Group C1 | EXPERIMENTAL | - |
| Cohort C Treatment Group C2 | EXPERIMENTAL | - |
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VTX2735 | DRUG | Dose A, Daily |
Inclusion Criteria: * Participants are male or female ≥ 18 years up to ≤ 75 years of age. * Capable of giving signed informed consent and able to comply with the protocol * Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event * Ongoing sympt...
VTX2735 is an investigational small molecule being developed for recurrent pericarditis and cryopyrin associated periodic syndrome, both rare diseases. It is currently in Phase 2 clinical development and has not been approved by the FDA.
VTX2735 targets NLRP3, acting as an inhibitor of this protein. By inhibiting NLRP3, the drug aims to modulate the inflammatory pathway involved in the conditions it is being studied for, including recurrent pericarditis and cryopyrin associated periodic syndrome.
VTX2735 is being developed by Ventyx Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VTYX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with rare inflammatory diseases.
VTX2735 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval. Clinical trials are ongoing to assess its potential as a treatment for recurrent pericarditis and cryopyrin associated periodic syndrome.
VTX2735 is being studied in two Phase 2 trials. NCT05812781, a completed study in patients with cryopyrin associated periodic syndrome, enrolled 7 participants in the United States. NCT06836232, an open-label pilot study in recurrent pericarditis, is currently recruiting up to 50 participants in the United States and Canada.
No alternative names for VTX2735 have been disclosed. It is identified solely by its development code, VTX2735, and is being investigated by Ventyx Biosciences for the treatment of recurrent pericarditis and cryopyrin associated periodic syndrome.